-transparent.png){kind=logo}
The antiviral xanthate compound tricyclodecan-9-yl-xanthogenate (code name D609) is capable of inhibiting DNA and RNA viruses in vitro. It can also inhibit the shedding of infectious HIV into the tissue culture medium from chronically infected lymphoma cells (KE37-III) as shown by infectivity assays and Western blots of the supernatant. HIV-specific proteins, however, were accumulated intracellularly. The initiation of a de novo HIV replication after infection of permissive KE37-1 cells was completely inhibited at concentrations of D609 which still permitted mitotic divisions of the cells. Furthermore, the selective antiviral activity of the xanthate compound was evidenced by the absence of HIV replicative intermediate DNA. The expression of cellular genes, such as c-myc, remained unimpaired within these cells.
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
September 1997,
Antiviral research,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
August 1988,
Experimental cell research,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
March 1991,
Lancet (London, England),
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
December 2009,
Current opinion in infectious diseases,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
December 1987,
The Journal of general virology,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
July 1989,
Biochemical and biophysical research communications,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
January 2016,
AIDS research and therapy,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
February 2010,
Yao xue xue bao = Acta pharmaceutica Sinica,
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
December 1988,
AIDS (London, England),
W Mellert, and
E Amtmann, and
V Erfle, and
G Sauer
March 2009,
Proceedings of the National Academy of Sciences of the United States of America,
